Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888653 | 0.79 | EPHX1 (0.33) | TSHRALDH1A1LMNANFKB1BLM | |
| SCHEMBL17030024 | 0.79 | KDM4C (0.42) | KDM4CTSHRALDH1A1MAPTNAALAD2 | |
| SCHEMBL18991310 | 0.78 | TSHR (0.38) | KDM4CTSHRALDH1A1LMNANFKB1 | |
| SCHEMBL18125958 | 0.77 | KDM4C (0.48) | KDM4CTSHRALDH1A1MAPTNAALAD2 | |
| SCHEMBL5499651 | 0.76 | CRBN (0.32) | TSHRLMNANFKB1BLMPMP22 | |
| SCHEMBL6471708 | 0.74 | KDM4C (0.46) | KDM4CTSHRALDH1A1NFKB1MAPT | |
| SCHEMBL25306945 | 0.74 | ALDH1A1 (0.36) | TSHRALDH1A1LMNANFKB1MAPT | |
| SCHEMBL18312018 | 0.74 | DGAT1 (0.39) | TSHRALDH1A1LMNANFKB1BLM | |
| SCHEMBL30066024 | 0.74 | KDM4C (0.42) | KDM4CTSHRALDH1A1MAPTCYP1A2 | |
| SCHEMBL29732540 | 0.74 | TSHR (0.35) | TSHRALDH1A1LMNANFKB1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116718697-A | Metabolite screening method for prolonging QTc interval of drug-resistant pulmonary tuberculosis and application | 首都医科大学附属北京胸科医院 | 2023-09-08 | — | — | CN | claimed |
| CN-111060607-B | Metabolite combination for pre-operation early warning of transplanted kidney delayed recovery after cardiac death and screening method thereof | ZHEJIANG UNIVERSITY (CN) | 2021-08-31 | — | — | CN | claimed |
| CN-111060607-A | Metabolite combination for pre-operation early warning of transplanted kidney delayed recovery after cardiac death and screening method thereof | 浙江大学 | 2020-04-24 | — | — | CN | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| US-20100116691-A1 | BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2010-05-13 | — | — | US | claimed |
| CN-118425362-B | Organic acid metabolism marker for distinguishing wild and cultivated four-big domestic fish and application thereof | 中国水产科学研究院长江水产研究所 | 2024-12-10 | — | — | CN | disclosed |
| US-20240358735-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-10-31 | — | — | US | disclosed |
| EP-4392037-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | Boyce Thompson Institute for Plant Research Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-117986066-A | Microbial fertilizer for improving yield of hybrid seed production rice and preparation method thereof | 江西瑞博特生物科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-116718697-A | Metabolite screening method for prolonging QTc interval of drug-resistant pulmonary tuberculosis and application | 首都医科大学附属北京胸科医院 | 2023-09-08 | — | — | CN | disclosed |
| CN-116554076-A | Application of hydrazide compound as derivatization reagent | 复旦大学 | 2023-08-08 | — | — | CN | disclosed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1550725-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | KDM4C 1980/4885TSHR 4535/4885ALDH1A1 443/4885 |
| US-20240358735-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | MAG, PMP22, B3GAT3 | KDM4C 2001/4885TSHR 4851/4885ALDH1A1 3030/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | KDM4C 4512/4885TSHR 4811/4885ALDH1A1 2677/4885 |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | DNPEP, ASPH, APP | KDM4C 4386/4885TSHR 4736/4885ALDH1A1 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.